aod9604 clinical trials weight loss efficacy AOD-9604 Appetite-Neutral Fat Process: Management Without Hunger Changes The Journey of AOD-9604: From

At Relive Hendersonville, this peptide treatment is empowering individuals to finally achieve their weight loss goalswithout the risks and pitfalls associated with traditional methods

Enicepatide: Roche's CT-388 Hits 22.5% at ADA 2026 Roche's enicepatide (CT-388) hit 22.5% placebo-adjusted weight loss at ADA 2026

Acute AOD9604 exposure, however, still increased energy expenditure and fat oxidation in the knockout animals

By reducing NNMT catalytic activity, the compound allows researchers to evaluate how limiting nicotinamide methylation influences: In vitro and in vivo experimental models (non-clinical, non-human) have demonstrated that NNMT suppression leads to measurable changes in cellular energy markers and adipocyte behavior